Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer
Thiru Prasanna, Rachel Wong, Timothy Price, Jeremy Shapiro, Jeanne Tie, Hui-Li Wong, Louise Nott, David Roder, Margaret Lee, Suzanne Kosmider, Azim Jalali, Matthew Burge, Robert Padbury, Guy Maddern, Scott Carruthers, James Moore, Michael Sorich, Christos S Karapetis, Peter Gibbs, Desmond Yip
CURRENT PROBLEMS IN CANCER | MOSBY-ELSEVIER | Published : 2021
BACKGROUND: Resection of oligometastases improves survival in metastatic colorectal cancer (mCRC). It is unclear whether the benefit is consistent for BRAF V600E mutant (MT) and wild type (WT) mCRC. This retrospective analysis explores the influence of BRAF MT on survival after metastasectomy. METHODS: Overall survival (OS) and recurrence-free survival (RFS) for BRAF MT and WT mCRC were evaluated. Survival was also analyzed in the cohort of BRAF MT with or without metastasectomy. RESULTS: Five hundred and thirteen patients who had undergone metastasectomy were identified, 6% were BRAF-MT. Median age 63. Median OS in BRAF MT vs WT: 25.7 vs 48.5 months (hazard ratio [HR] 1.95; 1.18-3.22). Howe..View full abstract
Roche Products Pty Limited has provided financial assistance for the development, installation, and maintenance of the BioGridTRACC registry. The South Australian State Government has provided support for the maintenance of the SA Metastatic Colorectal Cancer Registry.